Who are Epinastine Nasal Spray's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bepreve, bepotastine besilate ophthalmic solution, Levocetirizine (drug), olopatadine 0.2% ophthalmic solution, Cetirizine Dry Syrup.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epinastine-nasal-spray.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Epinastine Nasal Spray — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epinastine Nasal Spray (Epinastine Nasal Spray) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histamine H1-receptor antagonist. Area: Respiratory.

phase 2 Histamine H1-receptor antagonist H1-receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Epinastine Nasal Spray (Epinastine Nasal Spray) — Merck Sharp & Dohme LLC. Epinastine is a selective histamine H1-receptor antagonist that blocks the action of histamine on nasal mucosa, reducing symptoms of allergic rhinitis.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epinastine Nasal Spray TARGET	Epinastine Nasal Spray	Merck Sharp & Dohme LLC	phase 2	Histamine H1-receptor antagonist	H1-receptor
Bepreve	BEPOTASTINE	Bausch Health	marketed	Histamine-1 Receptor Antagonist	H1-receptor, mast cells	2009-01-01
bepotastine besilate ophthalmic solution	bepotastine besilate ophthalmic solution	Bausch & Lomb Incorporated	marketed		H1-receptor, mast cells
Levocetirizine (drug)	Levocetirizine (drug)	UCB Pharma	marketed	H1-receptor antagonist (second-generation antihistamine)	H1-receptor
olopatadine 0.2% ophthalmic solution	olopatadine 0.2% ophthalmic solution	Allergan	marketed	H1-receptor antagonist	H1-receptor
Cetirizine Dry Syrup	Cetirizine Dry Syrup	GlaxoSmithKline	phase 3	H1-receptor antagonist (second-generation antihistamine)	H1-receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histamine H1-receptor antagonist class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epinastine Nasal Spray — Competitive Intelligence Brief. https://druglandscape.com/ci/epinastine-nasal-spray. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab